IN THE CLAIMS

Claims 1 through 30 cancelled in the first Preliminary Amendment upon filing this a application.

Claims 31 through 50 - please cancel after entry of the following new claims 51-62.

Listing of the Claims:

Claims 1-50 (cancelled)

51. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises about 50 wt% of ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

52. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises about 70 wt% of ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

53. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises about 80 wt% of ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

54. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises about 80 wt% of ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at

least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 3:1 over the 24 hour period.

55. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises about 90 wt% of ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

56. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 50 wt% of (R)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

57. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 70 wt% of (R)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

58. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 80 wt% of (R)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

59. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 50 wt% of (S)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when

administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

60. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 70 wt% of (S)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

61. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form comprises at least about 80 wt% of (S)-ranolazine and the admixture of at least one pharmaceutically acceptable excipient, said dosage form when administered at least once during a 24 hour period provides a peak to trough level plasma ranolazine level that does not exceed 4:1 over the 24 hour period.

62. (New) A pharmaceutical dosage form for delivering ranolazine to a human, wherein the dosage form inhibits the release of ranolazine from the dosage form when subjected to an aqueous environment having a pH such as that found in the stomach and promotes the release of a therapeutically effective amount of ranolazine in an aqueous environment having a pH above about 4.5.